Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19844821 | 1.00 | KDM4E (0.54) | KDM4EKMT2ASIGMAR1LTA4H | |
| SCHEMBL19844793 | 1.00 | KDM4E (0.54) | KDM4EKMT2ASIGMAR1LTA4H | |
| SCHEMBL12384539 | 0.92 | SLC6A3 (0.56) | KDM4ESIGMAR1 | |
| SCHEMBL10281961 | 0.82 | CYP2D6 (0.60) | KDM4E | |
| SCHEMBL19844795 | 0.82 | CYP2D6 (0.60) | KDM4E | |
| SCHEMBL13411424 | 0.82 | CYP2D6 (0.60) | KDM4E | |
| SCHEMBL13503942 | 0.82 | SIGMAR1 (0.64) | KMT2ASIGMAR1 | |
| SCHEMBL7979173 | 0.81 | L3MBTL1 (0.62) | KDM4EKMT2ASIGMAR1LTA4H | |
| SCHEMBL19850993 | 0.81 | L3MBTL1 (0.62) | KDM4EKMT2ASIGMAR1LTA4H | |
| SCHEMBL19851112 | 0.79 | CHRNB4 (0.58) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239861-B2 | Therapeutic compounds and uses thereof | GENETECH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239861-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC11 | KDM4E 1434/4885KMT2A 1878/4885SIGMAR1 1877/4885 |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC11 | KDM4E 1434/4885KMT2A 1878/4885SIGMAR1 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.